Add to ORKGWe present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in patients who are typically classified as having very good prognosis, not routinely offered standard chemotherapy, and who as such do not fit current UK prescribing guidelines for trastuzumab
BackgroundNo single standard treatment exists for patients with small, node-negative, human epiderma...
Use of chemotherapy for patients with estrogen receptor (ER)-positive breast cancer has been a confl...
Background: Recent data suggest that human epidermal growth factor receptor 2 (HER2)-low breast canc...
We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that hu...
The prognosis of patients with stage II–III Human Epidermal growth factor Receptor 2 (HER2)-positive...
Background: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplificati...
Limited data exist regarding the effect of adjuvant trastuzumab in women with small, node-negative, ...
Small (pT1a-b), node-negative (pN0) breast cancer generally has a good prognosis. However, HER2-posi...
Breast cancer positive for her2 (human epidermal growth factor receptor 2) is associated with a poor...
Introduction HER2 receptor expressing breast cancers are aggressive with poorer prognosis. They can ...
Patients with breast cancer are classified as having cells that over-express the human epidermal gro...
Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and...
Simple Summary Breast cancers (BCs) with a HER2 immunohistochemical score of 1+ or 2+ with negative ...
The treatment with adjuvant Trastuzumab in patients diagnosed with HER2+ small breast cancers is con...
Aim: HER2-positive (HER2+) breast cancer (BC) is a heterogeneous disease, with a minority of patient...
BackgroundNo single standard treatment exists for patients with small, node-negative, human epiderma...
Use of chemotherapy for patients with estrogen receptor (ER)-positive breast cancer has been a confl...
Background: Recent data suggest that human epidermal growth factor receptor 2 (HER2)-low breast canc...
We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that hu...
The prognosis of patients with stage II–III Human Epidermal growth factor Receptor 2 (HER2)-positive...
Background: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplificati...
Limited data exist regarding the effect of adjuvant trastuzumab in women with small, node-negative, ...
Small (pT1a-b), node-negative (pN0) breast cancer generally has a good prognosis. However, HER2-posi...
Breast cancer positive for her2 (human epidermal growth factor receptor 2) is associated with a poor...
Introduction HER2 receptor expressing breast cancers are aggressive with poorer prognosis. They can ...
Patients with breast cancer are classified as having cells that over-express the human epidermal gro...
Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and...
Simple Summary Breast cancers (BCs) with a HER2 immunohistochemical score of 1+ or 2+ with negative ...
The treatment with adjuvant Trastuzumab in patients diagnosed with HER2+ small breast cancers is con...
Aim: HER2-positive (HER2+) breast cancer (BC) is a heterogeneous disease, with a minority of patient...
BackgroundNo single standard treatment exists for patients with small, node-negative, human epiderma...
Use of chemotherapy for patients with estrogen receptor (ER)-positive breast cancer has been a confl...
Background: Recent data suggest that human epidermal growth factor receptor 2 (HER2)-low breast canc...